Rallybio Corporation On a mission to deliver groundbreaking therapies that transform the lives of patients with devastating rare diseases JUNE 2025 Acute focus on addressing areas of significant unmet need with a portfolio of potentially best-in- class therapies Innovative C5 inhibitor with first- and best-in-class potential for patients with severe refractory hematologic conditions RLYB116 clinical PK/PD study underway, data expected in 2H 2025 Potential first- and best-in-class ENPP1 inhibitor for patient ...